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Aims: To evaluate the impact of β-cell function on the efﬁcacy of lixisenatide, a once-daily prandial
glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes (T2D).
Materials and methods: In this post hoc analysis, patients from the Phase 3 GetGoal-M and GetGoal-S clinical
trials randomized to lixisenatide 20 μg once daily were stratiﬁed into quartiles by baseline β-cell function, as
measured by the secretory units of islet in transplantation (SUIT) index.
Results: Patients (N = 437) were distributed evenly among SUIT index quartiles 1 to 4 (lowest to highest β-cell
function). Clinical outcomes improved from baseline across all SUIT quartiles; mean changes at week 24 were:
glycated hemoglobin (HbA1c; % [mmol/mol]),−0.99 (−10.8),−0.87 (−9.5),−0.86 (−9.4),−0.83 (−9.1); and
postprandial plasma glucose (PPG; mmol/L), −7.9, −5.6, −5.5, −4.3 (overall effect P b 0.0001). Furthermore,
postprandial glucagon was reduced in all SUIT quartiles, while insulinogenic index improved only in patients with
higher baseline SUIT (overall effect P = 0.0286). No severe symptomatic hypoglycemic events were reported.
Conclusions: Lixisenatide treatment resulted in reductions in HbA1c and PPG levels across all SUIT quartiles. This
suggests that non-insulin-related actions of lixisenatide contribute to improved glycemic control in T2D.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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As β-cell function declines and type 2 diabetes (T2D) progresses, oral
antihyperglycemic drugs (OADs) become insufﬁcient and the addition of
other antihyperglycemic agents is required to maintain glycemic control
(Garber et al., 2013; Rydén et al., 2007). Studies have indicated that
adjunctive incretin-based agents, such as glucagon-like peptide-1
receptor agonists (GLP-1 RAs), can help patients successfully achieve
glycemic targets while potentially providing β-cell function beneﬁts
(Charbonnel & Cariou, 2011; Garber, 2010; Shomali, 2011). GLP-1 is a
naturally occurring peptide that is released within minutes of eating a
meal, and is known to suppress glucagon secretion from pancreatic
α-cells and stimulate insulin secretion by pancreatic β-cells in a
glucose-dependentmanner (Drucker, 2013;Holst, 2007;Nauck,Vardarli,
Deacon, Holst, &Meier, 2011; Seino, Fukushima, & Yabe, 2010). GLP-1 RA
therapies potentiate activity at GLP-1 receptors and therefore mimic the
effects of endogenous GLP-1, thereby stimulating glucose-dependent
insulin release and suppressing glucagon secretion, in addition to
promoting the delay of gastric emptying (Meier, 2012). Due to the
varying mechanisms of action associated with some GLP-1 RAs, such as
non-insulinotropic gastric emptying in the case of short-acting GLP-1
RAs, it has been postulated that such therapies could be efﬁcacious
regardless ofβ-cell function (Meier, 2012; Yabe&Seino, 2014); however,
this is yet to be established in a clinical setting.
Lixisenatide is a once-daily prandial GLP-1 RA for the treatment
of patients with T2D. Lixisenatide exerts insulinotropic effects
and is associated with a signiﬁcant delay in gastric emptying (Ahrén,
Leguizamo, Miossec, Saubadu, & Aronson, 2013; Fonseca et al., 2012;
Petersen, Knop, & Christensen, 2013; Riddle, Aronson, et al., 2013; Riddle,
Forst, et al., 2013; Seino, Min, Niemoeller, & Takami, 2012). In preclinical
studies, lixisenatide reduced the proportion of β-cells undergoing
apoptosis and prevented insulin depletion following lipotoxic stress
(Tews, Werner, & Eckel, 2008; Werner et al., 2008), although the β-cell
protective effects of lixisenatide are yet to be demonstrated in clinical
studies. Treatment of T2D with lixisenatide signiﬁcantly improves levels
of glycated hemoglobin (HbA1c), and is associated with pronounced
reductions in postprandial plasmaglucose (PPG) (Ahrén et al., 2013). The
signiﬁcantly improved control of PPG excursions seenwith lixisenatide is
likely a result of prolonged glucose absorption caused by delayed gastric
emptying (Lorenz et al., 2013). However, the relative contributions of
β-cell-dependent and -independent mechanisms towards the improved
glycemic control demonstrated by lixisenatide have yet to be established.
The Phase 3 GetGoal clinical trial program evaluated the use of
lixisenatide in combination with OADs and/or basal insulin in adult
patients with T2D. It was reported that lixisenatide improves glycemic
control and has a favorable tolerability proﬁle and acceptable adverse
event frequency, supporting lixisenatide use for the treatment of T2D
(Ahrén et al., 2013; Fonseca et al., 2012; Pinget et al., 2013; Riddle,
Aronson, et al., 2013; Riddle, Forst, et al., 2013; Rosenstock et al., 2013;
Seino et al., 2012).
As β-cell function varied in the GetGoal clinical trial program due
to the different patient populations evaluated, it allowed us to
evaluate the efﬁcacy and safety of lixisenatide treatment plus OADs
(metformin and/or a sulfonylurea [SU]) in patients with T2D and
varying levels of β-cell function. In this study, we measured β-cell
function using the secretory units of islet in transplantation (SUIT)
index (Yamada et al., 2006), and used these analyses to investigate the
effect of lixisenatide in patients with varying β-cell function.
2. Materials and methods
This was a post hoc pooled analysis of data from the previously
reported 24-week main treatment periods of the randomized,
double-blind, placebo-controlled, parallel-group, multicentre, Phase
3 GetGoal-M (NCT00712673) and GetGoal-S (NCT00713830) trials.
The methodology and primary results of these studies have beenreported previously (Ahrén et al., 2013; Rosenstock et al., 2014).
Brieﬂy, patients included in the GetGoal-M and GetGoal-S trials had
been diagnosed with T2D at least 1 year before screening, and had
HbA1c ≥7% (53 mmol/mol) and ≤10% (86 mmol/mol) at screening.
Patients in the GetGoal-M trials had been treated with metformin at a
stable dose of at least 1.5 g/day for at least 3 months before the
screening visit, whereas patients included in the GetGoal-S trial had
been treated with an SU with or without metformin at a stable dose of
at least 1.5 g/day (except at least 0.75 g/day in Japan and 1.0 g/day in
South Korea) for at least 3 months before the screening visit. In both
GetGoal-M and GetGoal-S, patients were enrolled and randomized to
receive lixisenatide (Lyxumia®, Sanoﬁ, Paris, France) 20 μg once daily
or placebo, both plus background OADs. In both studies, the 600 kcal
standardized liquid meal (400 mL Ensure Plus; Abbott Nutrition,
Columbus, OH, USA; comprising 53.8% carbohydrate, 16.7% protein
and 29.5% fat) was given 30 min after drug administration at baseline
and at the end of the main 24-week treatment period (hereafter
referred to as ‘end of study’).
Lixisenatide was administered subcutaneously using the Opticlik®
(Sanoﬁ, Paris, France) self-injector device. Lixisenatide 10 μg once
daily was administered for 1 week, then 15 μg once daily for 1 week,
followed by the maintenance dose of 20 μg once daily until the end of
the study.
This study complied with recommendations of the 18th World
Health Congress (Helsinki, 1964) and all applicable amendments. The
protocols also complied with the laws and regulations, as well as any
applicable guidelines, of the countries where the study was
conducted. Informed consent was obtained prior to the conduct of
any study-related procedures.
2.1. Design of the post hoc analysis
The post hoc analyses presented here were based on the modiﬁed
intent-to-treat (mITT) population (N = 437), which comprised all
patients from the GetGoal-M (n = 195) and GetGoal-S (n = 242)
trials who were randomized to receive lixisenatide, in addition to
previous OAD therapy, and had an HbA1c measurement at baseline
and end of study. SUIT index estimates β-cell function based on a
single fasting blood sample and, as such, is a useful tool in the clinical
management of diabetes. SUIT index (nmol/mmol) was calculated for
each patient in the mITT population based on their baseline
characteristics, using the formula: 250 × fasting C-peptide nmol/L/
fasting plasma glucose mmol/L − 3.43, where a greater SUIT index
score indicates better β-cell function (Yamada et al., 2006). Patients
were classiﬁed into quartiles according to median SUIT values, where
patients in quartile 1 had the lowest baseline SUIT value (lowest β-cell
function) and those in quartile 4 had the highest baseline SUIT value
(highest β-cell function). The threshold values for SUIT quartiles 1–4
were b24.5, ≥24.5–b34.7, ≥34.7–b49.6, and ≥49.6 nmol/mmol,
respectively.
Clinical outcomes at baseline and end of study were analyzed for
each quartile and included: change in HbA1c and the proportion of
patients achieving b7% (53 mmol/mol) target; change in fasting plasma
glucose (FPG) and the proportion of patients achieving b6.1 mmol/L
target; change in 2-h PPG post-standardized meal test and the
proportion of patients achievingb10.0 mmol/L target; absolute changes
in body weight and body mass index (BMI); change in insulinogenic
index (deﬁned as [insulin at 2-h postprandial − insulin at post-
lixisenatide injection, preprandial]/[glucose at 2-h postprandial −glucose
at post-lixisenatide injection, preprandial]); and change in postprandial
glucagon.
Symptomatic hypoglycemia and severe symptomatic hypoglyce-
mia were monitored throughout the trials. Symptomatic hypoglyce-
mia was deﬁned as an event with clinical symptoms that were
considered to be a result of a hypoglycemic episode with plasma
glucose b3.3 mmol/L, or was associated with prompt recovery after
Table 1
Lixisenatide patient baseline demographics and clinical characteristics (mITT population).
Characteristic SUIT quartile 1
(b24.5 nmol/mmol)
(n = 110)
SUIT quartile 2
(≥24.5–b34.7 nmol/mmol)
(n = 109)
SUIT quartile 3
(≥34.7–b49.6 nmol/mmol)
(n = 109)
SUIT quartile 4
(≥49.6 nmol/mmol)
(n =109)
P-value⁎
Age, years 55.7 (10.1) 55.9 (9.4) 55.5 (9.6) 55.9 (9.6) 0.9875
Female, n (%) 48 (43.6) 68 (62.4) 62 (56.9) 64 (58.7) 0.0307
Body weight, kg 75.5 (16.5) 85.7 (22.8) 89.8 (25.2) 95.7 (23.4) b0.0001
BMI, kg/m2 27.7 (4.9) 31.6 (7.3) 32.8 (7.2) 35.0 (7.6) b0.0001
Ethnicity, n (%) b0.0001
Asian 59 (53.6) 33 (30.3) 27 (24.8) 19 (17.4)
Black/African American 4 (3.6) 3 (2.8) 9 (8.3) 3 (2.8)
White 46 (41.8) 73 (67.0) 72 (66.1) 86 (78.9)
Other 1 (0.9) 0 (−) 1 (0.9) 1 (0.9)
T2D duration, years 9.9 (6.1) 8.0 (5.6) 7.5 (6.1) 7.0 (5.9) 0.0019
OAD use, n (%)
Metformin 96 (87.3) 97 (89.0) 95 (87.2) 98 (89.9) 0.9022
SU 79 (71.8) 61 (56.0) 55 (50.5) 47 (43.1) 0.0002
OAD history, years 5.8 (4.3)§ 5.1 (4.1) 4.9 (5.0)‡ 4.5 (4.6) 0.2320
HbA1c, % 8.55 (0.86) 8.30 (0.77) 8.09 (0.84) 7.72 (0.83) b0.0001
mmol/mol 70 (9.4) 67 (8.4) 65 (9.2) 61 (9.1)
FPG, mmol/L 10.1 (2.0) 9.6 (2.1) 9.3 (1.8) 8.6 (1.8) b0.0001
PPG post-meal test, mmol/L 19.2 (4.2)† 16.4 (3.2)‡ 15.6 (3.4)§ 13.5 (3.4) b0.0001
SUIT index, nmol/mmol 18.2 (4.8) 29.9 (2.9) 40.9 (3.9) 90.2 (201.9) b0.0001
Data are mean (SD), unless otherwise stated.
ANOVA, analysis of variance; BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; mITT, modiﬁed intent-to-treat; OAD, oral antidiabetic drug; PPG,
postprandial plasma glucose; SD, standard deviation; SU, sulfonylurea; SUIT, secretory units of islet in transplantation.
⁎ ANOVA test for continuous variables and chi-square test for categorical variables, with the P-value denoting the difference in effect of baseline SUIT index across SUIT quartiles.
† n = 109.
‡ n = 108.
§ n = 107.
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Severe symptomatic hypoglycemia was deﬁned as an event with
clinical symptoms that were considered to be a result of a
hypoglycemic episode and required the assistance of another person,
with plasma glucose b2.0 mmol/L, if available.
2.2. Statistical methods
The mITT population was used to conduct post hoc analyses.
Descriptive statistics for the SUIT quartiles were used to describe
patient baseline characteristics and safety outcome measurements.
Count and mean (standard deviation [SD]) values were reported for
continuous variables (age, weight, HbA1c, FPG and PPG). Patient
baseline characteristics, glycemic outcomes and safety outcome
measurements for the SUIT quartiles were compared using an analysis
of variance test for continuous variables and a chi-square test for
categorical variables with the P-value denoting the difference in
overall effect across SUIT quartiles (P-values b 0.05 indicated statis-
tical signiﬁcance). Receiver operator curve (ROC) analyses were
carried out to assess the sensitivity and speciﬁcity of using baseline
SUIT index score to predict the likelihood of achieving glycemic
targets at week 24, including FPG b7.2 mmol/L, PPG b10.0 mmol/L
and HbA1c b7% (53 mmol/mol).
3. Results
Patient demographics and baseline characteristics of the safety
populations from the GetGoal-M and GetGoal-S trials have been
reported previously (Ahrén et al., 2013; Rosenstock et al., 2014).
The mITT population for this analysis was distributed among SUIT
quartiles (SUIT quartile 1 [b24.5 nmol/mmol], n = 110; quartile 2
[≥24.5–b34.7 nmol/mmol], n = 109; quartile 3 [≥34.7–b49.6 nmol/mmol],
n = 109; quartile 4 [≥49.6 nmol/mmol], n = 109). Baseline demographics
and clinical characteristics according to SUIT index quartile are shown
(Table 1). Sex was signiﬁcantly different among quartiles (P = 0.0307
for overall effect), with a greater proportion of women versus men in
quartiles 2, 3 and 4. Bodyweight and BMIwere both greater for patientswith higher β-cell function (P b 0.0001 for overall effect of both).
Patient ethnicitywas signiﬁcantly different amongquartiles (P b 0.0001
for overall effect), with higher proportions of white versus Asian
patients in quartiles 2, 3 and 4 compared with similar proportions of
white andAsianpatients inquartile 1. As expected, disease durationwas
longer for patients with reduced baseline β-cell function (P = 0.0019
for overall effect), and glycemic parameters were lower for patients
with higher β-cell function (P b 0.0001 for overall effect for HbA1c, FPG
and PPG).
3.1. SUIT index scores at baseline and end of study
Baselinemean (SD) SUIT index scores were 18.2 (4.8) nmol/mmol for
quartile 1, 29.9 (2.9) nmol/mmol for quartile 2, 40.9 (3.9) nmol/mmol for
quartile 3 and 90.2 (201.9) nmol/mmol for quartile 4 (P b 0 .0001 for
overall effect; Table 1). At week 24, absolute mean (SD) SUIT scores
remained greater in patients with higher β-cell function at baseline
(P b 0.0001 for overall effect; quartile 1 34.0 [17.7], quartile 2 54.7 [54.3],
quartile361.8 [25.4] andquartile489.0 [58.3]nmol/mmol), and themean
(SD) changes in SUIT index score from baseline to end of studywere 15.8
(16.8), 24.8 (53.8), 20.9 (25.4) and −1.2 (215.3) nmol/mmol for SUIT
quartiles1, 2, 3 and4, respectively. Theoverall effect of baselineSUIT index
on the mean changes from baseline of the SUIT index scores was not
signiﬁcant (P = 0.3299). However, the individual improvements in SUIT
index for quartiles 1 to 3 were signiﬁcant (P b 0.0001) for each quartile
change from baseline.
3.2. Clinical outcomes according to SUIT index
Patients with lower β-cell function at baseline had higher baseline
levels of HbA1c (P b 0.0001 for overall effect; Table 1), with fewer
patients achieving HbA1c b7% (53 mmol/mol) (P = 0.0021 for
overall effect; Fig. 1A). Improvements in the mean levels of HbA1c
from baseline to end of study were seen in each SUIT quartile, and the
overall effect of baseline SUIT index on mean changes from baseline
was not signiﬁcant between quartiles (P = 0.5756; Fig. 1B). However,
as would be expected based on the differences in baseline mean SUIT
1388 D. Yabe et al. / Journal of Diabetes and Its Complications 30 (2016) 1385–1392scores, higher proportions of patients in quartile 3 and 4 achieved
HbA1c b7% (53 mmol/mol) by week 24 (P b 0.0001 for overall effect;
Fig. 1A).
Patients with lower β-cell function at baseline had higher baseline
FPG (P b 0.0001 for overall effect between SUIT quartiles; Table 1),P = 0.0017
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of patients achieving target FPG b6.1 mmol/L at week 24 (P = 0.0618,
Fig. 1C).
Patients with lower β-cell function at baseline had higher baseline
levels of PPG post-meal test (P b 0.0001 for overall effect; Table 1),
with fewer patients achieving PPG b10.0 mmol/L (P = 0.0012 for
overall effect; Fig. 1E). Improvements in PPG from baseline to end of
study were seen in all SUIT quartiles (Fig. 1F). The greatest
improvements in PPG were seen in patients in the lower SUIT
quartiles (P b 0.0001 for overall effect, Fig. 1F), which were expected
given that these patients had the highest PPG levels at baseline.
However, greater proportions of patients in the higher SUIT quartiles
achieved PPG b10.0 mmol/L by week 24 (P = 0.0017 for overall
effect; Fig. 1E).
Baseline SUIT index had a signiﬁcant positive overall effect on the
changes in insulinogenic index post-meal test (P = 0.0286; Fig. 2A),
but not on the improvements in levels of plasma glucagon post-meal
test (P = 0.3618; Fig. 2B).
Reductions in body weight and BMI were seen across all four
quartiles (P = 0.7087 and P = 0.7238 for overall effect, respectively).
Improvements in body weight were −1.6, −1.6, −1.9 and −2.0 kg
for SUIT quartiles 1, 2, 3 and 4, respectively. Improvements in BMI
were−0.62,−0.60,−0.71 and−0.74 kg/m2 for SUIT quartiles 1, 2, 3
and 4, respectively.
3.3. Hypoglycemic events according to SUIT index
Symptomatic hypoglycemic events (plasma glucose b3.3 mmol/L)
were reported in 12 (10.9%) patients in quartile 1, 13 (11.9%) in
quartile 2, 13 (11.9%) in quartile 3 and 5 (4.6%) in quartile 4. Baseline
SUIT index did not have a signiﬁcant overall effect on the number of
patients who reported symptomatic hypoglycemic events (P = 0.2034).
No severe symptomatic hypoglycemic events (requiring the assistance of
another person) occurred in any SUIT quartile.
3.4. Baseline SUIT index as a predictor of glycemic outcomes
A SUIT index cut-off value of N36 nmol/mmol was indicated by
ROC analysis of the sensitivity and selectivity trade-off as predicting
FPG b7.2 mmol/L at end of study (Supplemental Fig. 1A). A SUIT index–863.4
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Fig. 2. Improvements in (A) insulinogenic index* and (B) plasma glucagon levels post-me
≥24.5–b34.7, ≥34.7–b49.6 and ≥49.6 nmol/mmol, respectively. P-values denoting the differen
is deﬁned as (insulin at 2 hours postprandial – insulin at post-lixisenatide injection, pr
preprandial), with a unit of 10*pmol/mmol, or dL*pmol/mmol*L.cut-off value of N35 nmol/mmol was indicated by ROC analysis as
predicting PPG b10.0 mmol/L (Supplemental Fig. 1B) and HbA1c b7%
(53 mmol/mol) (Supplemental Fig. 1C) at end of study.4. Discussion
Here we evaluated the efﬁcacy and safety of lixisenatide in
patients with T2D and varying levels of baseline β-cell function, with
uncontrolled glycemia despite treatment with OADs, including
metformin alone, or an SU with or without metformin. The main
ﬁnding of the study was that lixisenatide improved glycemic control
irrespective of β-cell function, as assessed by SUIT index. Differences
in baseline β-cell function were associated with differences in disease
characteristics and baseline glycemic parameters and, as expected,
patients with worse baseline β-cell function had longer disease
duration and higher levels of hyperglycemia. β-cell function improved
over 24 weeks in this analysis, irrespective of baseline β-cell function,
and as measured by change from baseline in SUIT index score.
However, it should be noted that this analysis is based on 24-week
data, which represent a relatively short time-frame in which to
evaluate changes in β-cell function.
Glycemic outcomes, including HbA1c, FPG and PPG post-meal test,
improved from baseline to week 24 across all baseline SUIT quartiles.
This is consistent with ﬁndings from the original GetGoal-M and
GetGoal-S trials, in which lixisenatide was associated with signiﬁcant
improvements in overall HbA1c, FPG and PPG versus placebo (Ahrén
et al., 2013; Rosenstock et al., 2014). As expected, and consistent with
the original studies, overall improvements in FPG seen in this analysis
were relatively small (between −0.8 and −1.0 mmol/L across
quartiles), whereas the improvements in PPG (between −4.3 and
−7.9 mmol/L across quartiles) were more substantial. The overall
effect of baseline SUIT index on reductions in HbA1c and FPG was not
signiﬁcant, suggesting that lixisenatide exerts a similar effect on
glycemic outcomes regardless of baseline SUIT score, although the
greatest improvement in HbA1c was still seen in patients with the
highest baseline levels of HbA1c. For PPG, the improvement from
baseline was particularly pronounced for patients with lower SUIT
index at baseline, likely because these patients had the highest
baseline PPG levels.–21.8
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across all SUIT index quartiles, we evaluated whether baseline β-cell
function could predict likelihood of achieving glycemic targets.
Despite seeing comparable mean improvements in glycemic out-
comes across SUIT quartiles, we found that baseline β-cell function
did have an overall effect on the proportions of patients reaching
glycemic targets at week 24 of lixisenatide as add-on to OAD therapy,
with greater proportions of patients in the higher versus lower
baseline SUIT quartiles reaching glycemic targets. Indeed, baseline
glycemic values were lower for patients in the higher SUIT index
quartiles, making it easier for them to achieve these low glycemic
targets at endpoint. Further examination of these data using a ROC
analysis conﬁrmed this by demonstrating that baseline SUIT index
values of N36, N35 and N35 nmol/mmol were able to predict patients
reaching target FPG, PPG and HbA1c levels, respectively, with an
accuracy of approximately 60% following treatment with lixisenatide
as add-on to OAD therapy. A previous study reported average SUIT
index values among patients with T2D who achieved FPG b7.2 mmol/
L with and without insulin to be 31.1% and 47.2%, respectively,
where SUIT index was deﬁned as: 1500 × fasting C-peptide immu-
noreactivity (ng/mL)/(FPG [mg/dL] − 61.7) (Funakoshi et al., 2011).
Treatment with lixisenatide has been shown previously to be
clinically efﬁcacious and tolerable in patients when administered as
add-on to basal insulin therapy due to the complementary effects of
basal insulin on FPG plus lixisenatide on PPG (Charbonnel, Bertolini,
Tinahones, Domingo, & Davies, 2014; Riddle, Aronson, et al., 2013;
Seino et al., 2012). Taken together, these data suggest that baseline
SUIT scores could be used to identify patients with T2D who may
respond well to potential basal insulin/lixisenatide combination
therapy, as has been used previously to identify patients requiring
multiple daily insulin injections (Fujiwara et al., 2013). Further
investigation to validate the association between SUIT index and
response to lixisenatide/OADs or basal insulin/lixisenatide combina-
tion therapy is warranted.
The overall improvements in glycemic parameters seen in patients
with low β-cell function, in particular the improvements in PPG in
these patients, support evidence that lixisenatide can mediate
glycemic control via β-cell-independent mechanisms such as gastric
emptying and glucagon release. Indeed, signiﬁcant reductions in PPG
with lixisenatide have been shown previously to be associated with
signiﬁcant slowing of gastric emptying and suppression of postpran-
dial glucagon in patients with T2D (Becker, Stechl, Msihid, & Kapitza,
2014; Kapitza et al., 2013). This is consistent with reports on the
mechanism of action of lixisenatide and other short-acting GLP-1 RAs
(Meier, 2012; Yabe & Seino, 2014), as well as pilot studies conducted in
patientswith type 1diabetes (Ghazi, Rink, Sherr, &Herold, 2014). Hence, as
lixisenatide can mediate its effects via β-cell-dependent and -independent
mechanisms, this should enable lixisenatide to be an effective and durable
treatment regardless of β-cell loss resulting from disease progression.
Long-acting GLP-1 RAs, on the other hand, exert their clinical effects
primarily by promoting the direct secretion of insulin and the indirect
suppression of glucagon release (Kapitza et al., 2013; Meier, 2012; Yabe &
Seino, 2014), yet also show efﬁcacy in patients with type 1 diabetes
(Kielgast, Krarup, Holst, & Madsbad, 2011).
Baseline SUIT index had no signiﬁcant overall effect on the
occurrence of symptomatic hypoglycemia, and no severe symptom-
atic hypoglycemic events were reported following lixisenatide
treatment in the GetGoal-M or GetGoal-S trials. Reports from the
lixisenatide clinical trial program suggest that lixisenatide is associ-
ated with a generally low risk of hypoglycemia (Ahrén et al., 2013;
Rosenstock et al., 2013), probably because the effects of lixisenatide
on insulin secretion are glucose-dependent.
SUIT index is a useful tool to assess β-cell function in patients with
T2D, since it has been shown to signiﬁcantly correlate with stimulated
C-peptide levels (r2 = 0.34, P b 0.001) (Kubota, Matsuba, Saito, Nabe,
& Seino, 2011; Yamada et al., 2006). SUIT index is similar to a fastingC-peptide/glucose ratio reported previously, which has been shown to
signiﬁcantly correlate with β-cell mass (Meier et al., 2009). An
additional beneﬁt of using the SUIT index is that calculations are
independent of the amount of exogenous insulin administered by the
patient (Yamada et al., 2006). This is in contrast to the homeostasis
model assessment estimated β-cell function (HOMA-b) method, for
example, where calculations are based on insulin levels (Wallace,
Levy, & Matthews, 2004). Furthermore, data published previously
have questioned the use of HOMA-b as a surrogate marker of insulin
secretion as it does not correlate with other measures of insulin
secretion (Ahrén & Larsson, 2002).
This is the ﬁrst time that SUIT index has been evaluated in patients
with T2D outside of Japan, although the current study suggests that
SUIT index can contribute to global clinical management decisions in
patients with T2D. Patient ethnicity was signiﬁcantly different among
SUIT quartiles. A greater proportion of Asian patients displayed lower
versus higher β-cell function at baseline; a greater proportion of white
patients demonstrated higher versus lower β-cell function at baseline.
However, this result may have been inﬂuenced by the characteristics
of the two trial populations: GetGoal-S recruited a higher proportion
of Asian patients than GetGoal-M (approximately 45% vs 8%,
respectively). As the entry requirements for GetGoal-S speciﬁed that
patients be inadequately controlled on an SU with or without
metformin, this may have been a population selected for lower
β-cell function than that in patients entered into GetGoal-M, which
speciﬁed only inadequate control with metformin. Therefore, the
apparently lower β-cell function in Asian patients should be regarded
with caution. There are also differences in the pathophysiology of
diabetes between Asian andwhite patients that may account for some
of this variation. Asian patients tend to have a pathophysiology of
insulin deﬁciency rather than insulin resistance, and there is some
evidence of underlying GLP-1 insufﬁciency in these patients (Seino
et al., 2010; Yabe et al., 2010; Yabe et al., 2012). Indeed, it has been
reported that Japanese people may be particularly susceptible to
developing T2D owing to particularly fragile β-cell function (Fukush-
ima, Suzuki, & Seino, 2004), and a decrease in β-cell function has been
proposed as a primary etiological factor in the development of T2D in
Asian Indians (Staimez et al., 2013).
Additionally, patients with higher β-cell function had increased
body weight and BMI versus patients with lower β-cell function.
These differences may also be associated with the characteristics of
the two trial populations, as the patient population of the GetGoal-M
trial wasmostly white and had higher baselinemean bodyweight and
BMI (Ahrén et al., 2013) compared with the patient population of the
GetGoal-S trial, which comprised a higher proportion of Asian patients
(Rosenstock et al., 2014). The increased use of SUs in patients with
lower β-cell function may also in part be due to the longer disease
duration in these patients versus patients with higher β-cell function.
Limitations of this study include the use of pooled data; patients in
the GetGoal-M trials had been treated with metformin, whereas
patients in the GetGoal-S trial had been treated with an SU with or
without metformin. Although murine and in vitro studies have
suggested that SUs may have an effect on incretin secretion (Nielsen
et al., 2007; Reimann et al., 2008), SUs have been shown to have little
effect on incretin secretion in Japanese patients with T2D (Yabe et al.,
2012). Furthermore, the increased use of OAD therapy in patientswith
lower versus higher β-cell function may be indicative of further
disease progression compared with patients who have only previ-
ously receivedmetformin. Data from the original studies highlight the
treatment effect of lixisenatide versus placebo; as such, SUIT analysis
of the placebo treatment arm to further conﬁrm the effect of
lixisenatide is warranted. Additionally, as baseline HbA1c is often
the most effective predictor of response for antidiabetic drugs, it
would have been interesting to correct the improvements seen in
HbA1c for the baseline levels of HbA1c. However, as SUIT index is
highly correlated with baseline HbA1c, correcting for HbA1c was not
1391D. Yabe et al. / Journal of Diabetes and Its Complications 30 (2016) 1385–1392possible as the patients would have been artiﬁcially forced (in a
mathematical sense) to have the same SUIT index level also, and this
would have resulted in very small patient numbers.
These data demonstrate that lixisenatide confers overall glycemic
control and pronounced reductions in PPG, and that lixisenatide is
well tolerated, across all levels of β-cell function, highlighting the
importance of the non-insulin-related actions of lixisenatide. Thus,
lixisenatide represents a useful treatment option in patients with T2D
who are inadequately controlled usingOADs, regardless ofβ-cell function.
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